Payment overview · 2025
General Payments
$310.86
17 reported records · 11 companies
Healthcare provider profile · identity verified
Donald Vogel, MD
Allopathic & Osteopathic Physicians|Family Medicine · SYLVANIA, OH · NPI 1437151297
Verified facts
What the public records show
CMS Open Payments records show Donald Vogel, MD received $310.86 in general payments during 2025 across 17 reported records.
ABBVIE INC. accounted for 26.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $82.42 | 26.5% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $45.85 | 14.8% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $34.43 | 11.1% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $29.58 | 9.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.79 | 7.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $19.16 | 6.2% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $16.35 | 5.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.86 | 5.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.59 | 5.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.50 | 4.7% | 1 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $14.33 | 4.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $278.59 | 16 |
| Education | $32.27 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $82.42 | 5 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $29.58 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $20.50 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19.16 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $16.35 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.86 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.59 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.50 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.50 | 1 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $14.33 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $13.93 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $13.93 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $13.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
54 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 554 | 125 |
| Atorvastatin Calcium | Atorvastatin Calcium | 414 | 109 |
| Lisinopril | Lisinopril | 407 | 110 |
| Simvastatin | Simvastatin | 352 | 88 |
| Amlodipine Besylate | Amlodipine Besylate | 327 | 89 |
| Metoprolol Succinate | Metoprolol Succinate | 313 | 87 |
| Omeprazole | Omeprazole | 280 | 73 |
| Alprazolam | Alprazolam | 270 | 58 |
| Fluoxetine Hcl | Fluoxetine Hcl | 243 | 51 |
| Losartan Potassium | Losartan Potassium | 212 | 55 |
| Pantoprazole Sodium | Pantoprazole Sodium | 212 | 55 |
| Gabapentin | Gabapentin | 193 | 40 |
| Prednisone | Prednisone | 191 | 90 |
| Metformin Hcl Er | Metformin Hcl | 189 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 179 | 52 |
| Citalopram Hbr | Citalopram Hydrobromide | 166 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 166 | 50 |
| Metformin Hcl | Metformin Hcl | 156 | 44 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 142 | 43 |
| Meloxicam | Meloxicam | 141 | 31 |
| Potassium Chloride | Potassium Chloride | 135 | 39 |
| Doxycycline Hyclate | Doxycycline Hyclate | 120 | 81 |
| Glipizide Er | Glipizide | 120 | 28 |
| Allopurinol | Allopurinol | 116 | 30 |
| Furosemide | Furosemide | 112 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 112 | 34 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 112 | 29 |
| Famotidine | Famotidine | 103 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 103 | 36 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 103 | 43 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 102 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 102 | 24 |
| Trazodone Hcl | Trazodone Hcl | 96 | 25 |
| Sertraline Hcl | Sertraline Hcl | 93 | 25 |
| Buspirone Hcl | Buspirone Hcl | 89 | 21 |
| Eliquis | Apixaban | 88 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 87 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 80 | 18 |
| Alendronate Sodium | Alendronate Sodium | 79 | 19 |
| Donepezil Hcl | Donepezil Hcl | 77 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 75 | 18 |
| Azithromycin | Azithromycin | 72 | 57 |
| Carvedilol | Carvedilol | 72 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 68 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 65 | 17 |
| Amoxicillin | Amoxicillin | 61 | 51 |
| Spironolactone | Spironolactone | 60 | 20 |
| Ondansetron Odt | Ondansetron | 57 | 22 |
| Atenolol | Atenolol | 54 | suppressed |
| Synthroid | Levothyroxine Sodium | 54 | 14 |
| Tramadol Hcl | Tramadol Hcl | 54 | 20 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 53 | 35 |
| Bupropion Xl | Bupropion Hcl | 52 | 11 |
| Glipizide | Glipizide | 52 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 48 | 24 |
| Promethazine Hcl | Promethazine Hcl | 46 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 42 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 41 | 12 |
| Ezetimibe | Ezetimibe | 37 | suppressed |
| Lansoprazole | Lansoprazole | 37 | suppressed |
| Nifedipine Er | Nifedipine | 37 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | suppressed |
| Naproxen | Naproxen | 35 | suppressed |
| Ozempic | Semaglutide | 35 | suppressed |
| Cephalexin | Cephalexin | 34 | 16 |
| Meclizine Hcl | Meclizine Hcl | 34 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 32 | 18 |
| Sumatriptan Succinate | Sumatriptan Succinate | 32 | suppressed |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Finasteride | Finasteride | 28 | suppressed |
| Primidone | Primidone | 28 | suppressed |
| Fluconazole | Fluconazole | 27 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Paroxetine Er | Paroxetine Hcl | 26 | suppressed |
| Clonazepam | Clonazepam | 25 | suppressed |
| Lorazepam | Lorazepam | 25 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Ibuprofen | Ibuprofen | 24 | 12 |
| Lidocaine | Lidocaine | 24 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Bumetanide | Bumetanide | 23 | suppressed |
| Celecoxib | Celecoxib | 23 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 23 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 23 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Mounjaro | Tirzepatide | 22 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Colchicine | Colchicine | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 20 | 15 |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | 11 |
| Diazepam | Diazepam | 19 | suppressed |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Oxycontin | Oxycodone Hcl | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 17 | 15 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Klor-Con M20 | Potassium Chloride | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Jardiance | Empagliflozin | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 13 |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Klor-Con M10 | Potassium Chloride | 13 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Cefdinir | Cefdinir | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Ciclopirox | Ciclopirox | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $310.86 · 17 records | ABBVIE INC. | AIRSUPRA, AREXVY, BEXSERO, Cologuard Collection Kit, FANAPT, INSPIRE, MOUNJARO, NEFFY, SHINGRIX, VRAYLAR, Wegovy, XIFAXAN, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error